National Cancer Institute (NCI)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).

3,257 total trials 326 currently recruiting 2051 completed early-phase tilt top decile by trial count

National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.

National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.

Top-decile sponsor footprint

National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

3,257 total, page 27 of 66

COMPLETED

Collection of Tissue Blocks or Slides From Patients With Cancer

NCT02810405
COMPLETED Phase 2

Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

NCT01466881
TERMINATED Phase 1

Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers

NCT01336387
COMPLETED Phase 1

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

NCT01352962
COMPLETED Phase 1

Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

NCT01440998
COMPLETED Phase 2

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

NCT01441063
TERMINATED Phase 1

ECI301 and Radiation for Advanced or Metastatic Cancer

NCT01441115
TERMINATED Phase 1

-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer

NCT01441128
COMPLETED Phase 1

Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

NCT01403415
COMPLETED Phase 1

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01369849
TERMINATED Phase 1

Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate

NCT01426334
TERMINATED Phase 2

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

NCT01468818
COMPLETED

Breath Test for Chemicals (Volatile Organic Compounds)

NCT01437033
COMPLETED Phase 1

TKM 080301 for Primary or Secondary Liver Cancer

NCT01437007
COMPLETED Phase 2

Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

NCT01349959
COMPLETED Phase 2

MR Image Guided Therapy in Prostate Cancer

NCT01377753
COMPLETED

Intestine Bacteria and Breast Cancer Risk

NCT01461070
COMPLETED Phase 1

Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer

NCT01383343
COMPLETED Phase 2

Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye

NCT01413191
COMPLETED Phase 2

Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

NCT01402284
COMPLETED Phase 1

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

NCT01381692
COMPLETED Phase 2

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

NCT01391962
COMPLETED Phase 1

Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma

NCT01266031
TERMINATED Early Phase 1

Amatuximab for High Mesothelin Cancers

NCT01413451
COMPLETED

BRCA Mutations in Latinas

NCT01251900
COMPLETED

The Ultrasound Study of Tamoxifen

NCT01582074
COMPLETED Phase 1

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

NCT01326702
COMPLETED Phase 2

TRC105 for Liver Cancer That Has Not Responded to Sorafenib

NCT01375569
COMPLETED

A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young Women

NCT00858078
TERMINATED Phase 2

Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

NCT01369875
COMPLETED

Follow-up Study of Late Effects of Periconceptional Folic Acid in Mothers and Offspring in the Community Intervention Program Population: The Chinese Children and Families Study

NCT01365975
COMPLETED

Livestock Contact and MRSA in Rural Areas

NCT01375621
COMPLETED Phase 1

Resveratrol in Postmenopausal Women With High Body Mass Index

NCT01370889
COMPLETED

Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma

NCT01418495
TERMINATED Phase 2

Lapatinib in Stage IV Melanoma With ERBB4 Mutations

NCT01264081
COMPLETED Phase 1

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

NCT01362790
TERMINATED

Evaluation of Molecular Markers in Adrenal Tumors

NCT01348698
COMPLETED Phase 2

Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia

NCT01361464
TERMINATED Phase 2

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

NCT01340794
TERMINATED Phase 1

Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma

NCT01369888
COMPLETED Phase 2

Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

NCT01286272
COMPLETED Phase 2

Carboplatin and Bevacizumab for Recurrent Ependymoma

NCT01295944
TERMINATED Phase 1

PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment

NCT01581541
COMPLETED Phase 1

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

NCT01344031
COMPLETED Phase 2

Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation

NCT01338987
TERMINATED Phase 1

Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal

NCT01341496
COMPLETED

Evaluation of Cancer Care Coordination in the National Cancer Institutes Community Cancer Center Programs

NCT01346280
TERMINATED Phase 2

Drosophila-generated CTL

NCT01271907
COMPLETED Phase 2

Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

NCT01253070
COMPLETED Phase 2

Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01349972
← Previous Page 27 of 66 Next →

Phase Distribution

PhaseTrial count
Phase 1 1199
Phase 2 1429
Phase 3 193

Therapeutic Areas

Advanced Malignant Solid Neoplasm 67
Refractory Malignant Solid Neoplasm 45
Metastatic Malignant Solid Neoplasm 38
Refractory Multiple Myeloma 35
Prostate Cancer 34
Refractory Lymphoma 33
Advanced Lymphoma 33
Acute Myeloid Leukemia 28
Unspecified Adult Solid Tumor, Protocol Specific 26
Breast Cancer 23

What is open in the National Cancer Institute (NCI) pipeline

326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).

Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).

Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Related

Compare saved trials side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.